Gilead profit misses Wall Street expectations as COVID drug sales decline
(Reuters) -Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%. Sales of the hospital-administered drug also know as remdesivir plunged 63% to $573 million for the quarter, well off analysts’ estimates of $697.6 million. The company said …
Gilead profit misses Wall Street expectations as COVID drug sales decline Read More »